(CRISP) Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
CRISP's overall goal is to develop methods that would facilitate shortening the observation period necessary to determine efficacy of treatment interventions in PKD patients. The following quotes are taken from some articles about the CRISP study:
MRI renal blood flow as a marker of disease severity in ADPKD.
PKD1 is more severe because more cysts develop earlier, not because they grow faster, implicating the disease gene in cyst initiation but not expansion.
There was significantly more urinary albumin in PKD1 cases. Kidney and cyst volumes consistently increased in both the PKD1 and PKD2.
Increases in cyst volume can be detected within 6 months.
CRISP The most relevant result was the evidence that MRI is the best procedure for estimating changes in cystic and renal volume in this disease over short follow-up periods.
The decline in renal function and disease progression in human ADPKD appears to be closely linked with the decline in renal blood flow.